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doi:10.1016/j.jmii.2011.11.003Background: Extended-spectrum b-lactamase (ESBL)-producing bacteria coexpressing AmpC
type b-lactamase (ACBL) are associated with the laboratory issue of false susceptibility to
third-generation cephalosporins. This study was to evaluate laboratory tests and clinical signif-
icance of bacteremic isolates of Escherichia coli and Klebsiella pneumoniae with both ESBL
and ACBL [dual-type lactamases (DTL)].
Methods: From 2006 to 2009, 78 E coli and 12 pneumoniae bacteremic isolates with reduced
susceptibility to cefotaxime (CTX) or ceftazidime (CAZ) were identified and relevant patients’
data were collected for analysis. Phenotypic and genotypic characterizations of these selected
isolates were determined by inhibitor-based assays and polymerase chain reactionebased
genetic analyses, respectively.
Results: Among the 90 isolates, 47 had DTL production. There was an increasing annual prev-
alence from 29% in 2006 to 56% in 2009 (pZ 0.02). Phenotypic assays had a sensitivity and
specificity of 57% (43/76) and 93% (13/14) for ESBL detection and 95% (58/61) and 34% (10/
29) for ACBL, respectively. Among the DTL-producing isolates, phenotypic assays yielded
a higher false negative rate of ESBL detection than that of ACBL detection (70% versus 6%),
while all false negative ESBL results were associated with ESBL genes other than blaCTx-M., Section 4, Ren-Ai Road, Da-An District, Taipei City 10630, Taiwan.
rg.tw (C.-H. Huang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
194 K. Tsui et al.The majority of the DTL-producing isolates were in the category of resistance to CTX (47/47,
100%) and CAZ (44/47, 94%) by the Clinical and Laboratory Standards Institute (CLSI) 2010
interpretive criteria, of which many were considered intermediate or fully susceptible to
CTX (25/47, 53%) and CAZ (15/47, 32%) by the previous ones (CLSI-2009). The DTL-producing
isolates exhibited a lower susceptibility rate to fluoroquinolones, aztreonam, and b-lactam/
lactamase inhibitors than those with either ESBL or ACBL alone. The use of indwelling cathe-
ters or nasogastric tubes was associated with bacteremia due to the DTL isolates, but the
mortality rates were not different among those due to isolates with ESBL, ACBL, or both. By
multivariate analysis, Pittsburg bacteremia score and Charlson comorbidity index were the
significant predictors for all-cause mortalities.
Conclusion: Bacteremic episodes due to DTL-producing E coli and K pneumoniae became
increasingly prevalent and were often associated with coresistance to antibiotics other than
b-lactams, but they were not associated with a worse prognosis than those due to ESBL- or
ACBL-producing bacteria.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Extended-spectrum b-lactamase (ESBL) and AmpC type
b-lactamase (ACBL) are class A and class B b-lactamases,
respectively, both conferring resistance to third-
generation cephalosporins (3GC-R) in Escherichia coli and
Klebsiella pneumoniae.1 These strains normally colonize
and spread among hospitalized patients, complicating the
treatment of nosocomial infections. However, community-
acquired ESBL producingeE coli, especially of CTX-M-type
ESBL, has now become a growing problem worldwide and
has changed the epidemiology of infections related
to antibiotic-resistant bacteria.2,3,4,5 Similarly, plasmid-
mediated ACBL-producing bacteria also serve as community-
based reservoirs for 3GC-R strains.3,6 Effective treatments
for infections caused by ESBL-producing E coli or K pneumo-
niae are limited to only a few antibiotics, including carba-
penems and noneb-lactam antibiotics.7 Antibiotics for
ACBL-producing bacteria, on the other hand, are chosen
based on the susceptibility testing results because there are
no established guidelines for ACBL identification; thus, most
laboratories do not routinely test for the presence of ACBL.
Laboratory confirmation of bacteria with ESBL activity
relies on the evidence of increased susceptibility to
extended-spectrum cephalosporins with an aid of class A
b-lactamase inhibitor, clavulanic acid. The inhibitor-based
assay is subjected to negative interference by concurrent
expression of other b-lactamases, including ACBL, because
different b-lactamases have variable susceptibility to
clavulanic acid.8 Since the coexistence of ESBL and ACBL is
not uncommon among Enterobacteriaceae, infections by
ESBL-producing bacteria are potentially underdiagnosed
and are thus inappropriately treated.9,10,11 Moreover,
clinical significance of infections by bacteria with dual
types of b-lactamases (DTL) was less addressed in the
literature than that by ESBL-producing bacteria. In this
study we first evaluated the efficacy of two inhibitor-based
tests for the prediction of ESBL or ACBL production in
bacteremic E coli and K pneumoniae isolates with reducedsusceptibility to 3-GC. Subsequently, the derived data
were combined with clinical information to elucidate risk
factors and clinical outcomes associated with different
types of b-lactamases.
Material and methods
Study population and definitions
Cathay General Hospital, an 800-bed tertiary care teaching
hospital in northern Taiwan, has an average of 27,000
admissions per year. From January 2006 through December
2009, all E coli and K pneumoniae isolates obtained from
blood cultures with reduced susceptibility to cefotaxime
(CTX) or ceftazidime (CAZ) were selected for this study.
Bacteria isolates from a patient in less than 1 month apart
were considered to be of the same isolate, and only the first
isolate was included for analysis unless they had different
antibiograms. Clinical information, including demographic
data, concurrent infection foci, comorbidity, severity of
sepsis at presentation, antimicrobial therapy, and 7-, 14-
and 30-day mortality rates were obtained from medical
records. The study was approved by the internal review
board of Cathay General Hospital.
Phenotypic assays for ESBL and ACBL, and
antibiotic susceptibility determination
The strains preserved at e80 C were recovered by resus-
pension of frozen stocks in brain-heart infusion broth and
plated on a 5% sheep blood agar, which were then incu-
bated for 24 hours before tests. Phenotypic methods to
detect ESBL or ACBL were inhibitor-based assays. The
presence of ESBL activity was indicated by the Clinical and
Laboratory Standards Institute (CLSI) disc diffusion tests, in
which a 5-mm increase in a zone diameter for either CTX
or CAZ in combination with ESBL inhibitor clavulanic acid
(CLA) was demonstrated to compare with either drug alone
Table 1 Phenotype-genotype correlation among isolates
with ESBL, ACBL, or both lactamases (DTL)
Phenotype Genotype (%)
ESBL, nZ 29 ACBL, nZ 14 DTL, nZ 47
ESBL 10 (34.5) 0 3a (6.4)
ACBL 0 13 (92.9) 33b (70.2)
DTL 19c (65.5) 1d (7.1) 11 (23.4)
a false-negative ACBL phenotype.
b false-negative ESBL phenotype.
c false-positive ACBL phenotype.
d false-positive ESBL phenotype.
ACBLZ AmpC type b-lactamase; DTLZ dual-type lactamases;
ESBLZ extended-spectrum b-lactamase.
ESBL and AmpC b-lactamase co-producers 195(CLSI M100-S20).12 ACBL activity was evaluated by the
double-disc synergy test (DDST) using an AmpC b-lactamase
inhibitor, 3-aminophenylboronic acid (APBA).13 The isolates
with ACBL-producing phenotype demonstrated a dumbbell-
like diffusion zone extending from either CTX or CAZ disc
toward an APBA-impregnated disc. Susceptibility to CTX
and CAZ was evaluated by the disc diffusion method,
whereas susceptibility to other antibiotics was determined
by the automatic Phoenix ID/AST instrument (Becton
Dickinson, Sparks, MD, USA).
Molecular characterization of ESBL and ACBL
Relevant b-lactamase genes(bla) were detected by PCRs and
gene specific primers. Primers for blaTEMblaSHV and blaCTx-M
families were used for the detection of ESBL genes as
described,14,15 and multiplex PCR was applied for plasmid-
borne AmpC genes (blaMOx, blaCIT, blaDHA, blaACC, blaEBC,
blaFOx).
16 Other lactamases known to confer CTX/CAZ resis-
tance, such as class A carbapenemase (blaKPC, blaPER) and
class B metallo-b-lactamases (blaVIM, blaIMP, blaSPM), were
subjected to genetic analysis as described.17,18,19
Statistical analysis
Data were collected and analyzed using Windows Office
Excel and SPSS software version 17 (SPSS Inc., Chicago, IL
USA). Changes in incidence over time were analyzed by
a Chi-square test for trend. Correlations between nominal
variables were assessed for significance by the Pearson
Chi-squared test or Fisher’s exact test. Multiple logistic
regression analysis was conducted to determine the inde-
pendent risk factors for mortality. A p value of 0.05 or less
was considered statistically significant.
Results
From January 2005 to December 2009, 90 episodes of
bacteremia caused by CTX and/or CAZ nonsusceptible E coli
(78; 85%) and K pneumoniae (12; 15%) were identified.
There was no bacteremia caused by CTX/CAZ-resistant
K oxytoca or Proteus mirabilis during the study period.
Forty-four and 77 isolates demonstrated ESBL- or ACBL-
producing phenotypes, respectively, including 31 isolates
manifesting DTL-phenotypes.
Molecular characterization of the b-lactamases revealed
different results from those of the phenotypic assays. ESBL
and ACBL genes were found in 76 and 61 isolates, respec-
tively, of which 47 had both ESBL and ACBL genes. The
major type of ESBL genes was blaTEM (62), followed by
blaCTx-M (35) and blaSHV (14). One-third (28; 37%) of the 76
isolates with ESBL genes contained more than one type of
ESBL gene. Of note, seven isolates with all three types of
ESBL genes were K pneumoniae. The major ACBL genes
found were blaCIT (54, 89%), followed by blaDHA (7, 11%).
Among the isolates with DTL genes, more negative
results by the phenotypic assay for the ESBL activity (33/47;
70%) were observed than those for the ACBL activity (3/47;
6%) (Table 1). Subsequent analysis revealed the absence of
ESBL-producing phenotype was only associated with ESBL
genes other than blaCTx-M. On the other hand, almost allcases (18/19; 95%) of false-positive ACBL-producing
phenotype were observed in ESBL-producing isolates with
blaCTx-M, suggesting some variants of blaCTx-M were
susceptible to class A and class C b-lactamase inhibitors.
Overall, the phenotypic assays for ESBL or ACBL activities
had a sensitivity and specificity of 57% (43/76) and 93%
(13/14), respectively, for the detection of isolates with
genes encoding ESBL and 95% (58/61) and 34% (10/29) for
those with genes encoding ACBL.
There was an increasing isolation rate over time of DTL-
producing bacteria among CTX- or CAZ-nonsusceptible
isolates, from 29% in 2006 to 56% in 2009 [pZ 0.02, Chi-
square for trend analysis (Fig. 1)]. These bacteria had
higher rates of coresistance to many antibiotics, such as
fluoroquinolones, monobactam, and b-lactam /b-lactamase
inhibitors (Fig. 2). More importantly, a higher rate of
resistance to piperacillin-tazobactam was seen in DTL-
producing isolates than ESBL- or ACBL-producing isolates.
Eighty-eight of the 90 isolates were susceptible to carba-
penems. Neither class A carbapenems (blaKPC, blaPER) nor
class B metallo-b-lactamases (blaVIM, blaIMP, blaSPM) were
identified in the carbapenem nonsusceptible isolates, sug-
gesting other mechanisms, including porin deficiency,
might mediate the carbapenem resistance. Finally, nearly
all DTL-producing bacteria were classified in the category
of resistance to CTX (47/47; 100%) and CAZ (44/47; 94%) by
the CLSI-2010 susceptibility breakpoints, although many of
them were intermediate or fully susceptible to CTX (25/47;
53%) and CAZ (15/47; 32%) if interpreted based on previous
(CLSI-2009) criteria (Table 2).
Univariate analysis of clinical features among cases of
bacteremia due to isolates with different b-lactamases
revealed an association of bacteremia due to DTL-
producing bacteria with indwelling catheters and endotra-
cheal/nasogastric tubes [p< 0.01 and 0.03, respectively
(Table 3)]. However, clinical outcomes, as assessed by
crude mortality rates at 7, 14, and 30 days, did not differ
significantly among ESBL-, ACBL- and DTL-producing
bacteremia. After adjusted for age, types of infection,
bacterial species, and acute bacteremia or comorbidity
indices, mortality rates remained similar among the three
groups (Table 4). However, a higher Pittsburgh bacteremia
score, which was not associated with a specific type of
b-lactamases, was a significant predictor for mortalities at
7, 14, and 30 days. In addition, Charlson comorbidity index
was associated only with 30-days morbidity.
Figure 1. Annual distribution of ESBL-, ACBL-, and DTL-producing Escherichia coli and Klebsiella pneumoniae causing bacter-
emia at a tertiary care hospital in north Taiwan from 2006 to 2009. ACBLZ AmpC type b-lactamase; DTLZ dual-type lactamases;
ESBLZ extended-spectrum b-lactamase.
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In this retrospective study of bacteremia caused by K
pneumoniae or E coli with reduced susceptibility to
extended-spectrum cephalosporins, more than one-half of
the episodes (47/90) were caused by DTL-producing
bacteria. DTL-producing isolates were associated with
higher rates of coresistance to fluoroquinolones, mono-
bactam, and piperacillin-tazobactam than ESBL-or ACBL-
producing isolates. Patients acquiring DTL-producingFigure 2. Antimicrobial susceptibilities of bacteremic isolates of
pneumoniae at a tertiary care hospital in north Taiwan from 200
lactamases; ESBLZ extended-spectrum b-lactamase.bacteremia more frequently had indwelling catheters,
endotracheal, or nasogastric tubes, but the mortality rate
was comparable with that caused by either ESBL- or ACBL-
producing isolates, suggesting coexistence of ESBL and
ACBL in bacteria did not pose additional risks for mortality
as compared with either type of b-lactamases alone.
The phenotypic assay for ESBLs is known to be interfered
by ACBL,20,21 as the latter is not inhibited by CLA. Thus,
failure to demonstrate ESBL phenotype in DTL-producing
bacteria may occur if the hydrolytic activity of ACBLESBL-, ACBL-, and DTL-producing Escherichia coli and Klebsiella
6 to 2009. ACBLZ AmpC type b-lactamase; DTLZ dual-type
Table 2 Third-generation cephalosporin susceptibilities of 90 isolates with reduced susceptibility to cefotaxime and/or
ceftazidime and producing ESBL, ACBL or both lactamases (DTL), as defined by 2009 and 2010 CLSI interpretive breakpoints
Antibiotic Isolate number (%)
ESBL, nZ 29 ACBL, nZ 14 DTL, nZ 47
CLSI-2010 CLSI-2009 CLSI-2010 CLSI-2009 CLSI-2010 CLSI-2009
Cefotaxime S 0 (0) 2 (6.9) 0 (0) 2 (14.3) 0 (0) 1 (2.1)
I 0 (0) 2 (6.9) 0 (0) 9 (64.3) 0 (0) 24 (51.1)
R 29 (100) 25 (86.2) 14 (100) 3 (21.4) 47 (100) 22 (46.8)
Ceftazidime S 22 (75.9) 24 (82.8) 0 (0) 1 (7.1) 1 (2.1) 3 (6.4)
I 2 (6.9) 1 (3.4) 1 (7.1) 5 (35.7) 2 (4.3) 12 (25.5)
R 5 (17.2) 4 (13.8) 13 (92.9) 8 (57.1) 44 (93.6) 32 (68.1)
ACBLZ AmpC type b-lactamase; CLSIZ Clinical and Laboratory Standards Institute; DTLZ dual-type lactamases; ESBLZ extended-
spectrum b-lactamase.
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activity. In our study the interference only occurred when
ESBL genes belonged to families other than the blaCTx-M
type. The lack of interference by ACBL was in part due to
unequal hydrolytic activities toward different 3-GCs
between CTX-MESBL and ACBL. Since CTX-MESBL preferen-
tially hydrolyze cefotaxime, CLA inhibitory effect is
adequate to warrant ESBL confirmation despite the coexis-
tence of ACBL activity. On the other hand, susceptibility to
ceftazidime in these isolates followed the patterns of ACBL-
producing isolates with minimal inhibition by CLA,Table 3 Demographics, predisposing factors, and clinical outco
and Klebsiella pneumoniae with ESBL, ACBL, or both lactamases
Variables ESBL (nZ 29)
Sex, male 11 (37.9)
Age (yr) >65 18 (62.1)
Diabetes 12 (41.4)
Chronic pulmonary disease 2 (6.9)
Heart failure 5 (17.2)
Renal insufficiency 5 (17.2)
Malignancy 15 (51.7)
Use of immunosuppressive drugs 5 (17.2)
Pittsburg bacteremia score >2 10 (34.5)
Charlson co-morbidity index >2 19 (65.5)
Severe sepsis or septic shock 16 (44.8)
Mode of infection
Hospital-acquired 10 (34.5)
Healthcare-associated 6 (20.7)
Community-acquired 13 (44.8)
Clinical syndromes
Urinary tract infection 17 (58.6)
Primary bloodstream infection 5 (15.6)
Biliary/gastrointestinal tract infection 7 (28.1)
Pneumonia 0 (0)
Mortality within
7 d 5 (17.2)
14 d 5 (17.2)
30 d 6 (20.7)
Note: Data are presented as case number (%).
ACBLZ AmpC type b-lactamase; DTLZ dual-type lactamases; ESBLZindicating that ceftazidime is a poorer substrate for
CTX-MESBL than for ACBL. Interestingly, almost all (18/19;
95%) ESBL-producing isolates concurrently exhibiting
ACBL phenotype had blaCTx-M, in which ACBL activity was
demonstrated only with ceftazidime but not with cefotax-
ime. Whether the substrate-specific effect is due to CTX-M
variants or is caused by occult ACBLs remains to be known.
Notwithstanding comparable clinical outcomes, core-
sistance to other antibiotics, such as fluoroquinolone,
monobactam, and b-lactam/lactamase inhibitors, was
more frequently observed in DTL-producing isolates than inmes of patients acquiring bacteremia due to Escherichia coli
(DTL)
ACBL (nZ 14) DTL (nZ 47) p values
8 (57.1) 24 (51.1) 0.4
10 (71.4) 29 (61.7) 0.79
4 (28.6) 16 (34) 0.68
1 (7.1) 7 (14.9) 0.49
0 (0) 7 (14.9) 0.27
2 (14.3) 9 (19.1) 0.72
4 (28.6) 18 (38.3) 0.30
0 (0) 3 (6.4) 0.12
6 (42.9) 21 (44.7) 0.67
7 (50) 33 (70.2) 0.38
8 (57.1) 28 (59.6) 0.93
0.29
4 (28.6) 23 (48.9)
3 (21.4) 13 (27.7)
7 (50) 11 (23.4)
0.30
4 (28.6) 22 (46.8)
3 (21.4) 10 (21.3)
7 (50) 12 (25.5)
0 (0) 3 (6.4)
1 (7.1) 9 (19.1) 0.57
1 (7.1) 11 (23.4) 0.38
4 (28.6) 18 (38.3) 0.27
extended-spectrum b-lactamase.
Table 4 Risk factors for mortality at three time points in patients acquiring bacteremia due to Escherichia coli and Klebsiella
pneumoniae with ESBL, ACBL, or both lactamases (DTL)
Adjusted odds ratio (95% confidence interval)
7-d mortality 14-d mortality 30-d mortality
Age (yr), > 65 vs 65 0.674 (0.124e3.672) 0.330 (0.066e1.651) 0.278 (0.070e1.102)
b-lactamase
ESBL Ref Ref Ref
ACBL 0.183 (0.012e2.748) 0.277 (0.020e3.767) 2.757 (0.404e18.821)
DTL 0.529 (0.106e2.626) 0.972 (0.230e4.111) 2.298 (0.601e8.779)
Source of bacteremia
No source Ref Ref Ref
Urinary tract 0.253 (0.036e1.766) 0.650 (0.119e3.535) 0.555 (0.131e2.343)
Biliary/gastrointestinal tract 0.790 (0.148e4.210) 0.757 (0.144e3.986) 0.476 (0.104e2.181)
Lung 14.921 (0.227e979) 12.995 (0.279e604) N
K pneumoniae vs E coli 0.630 (0.069e5.727) 0.585 (0.065e5.281) 3.684 (0.646e21.013)
Pitt bacteremia score >2 vs  2 14.557 (2.623e80.792)* 11.781 (2.659e52.198)* 9.806 (2.895e33.218)*
Charlson index >2 vs 2 4.274 (0.569e32.090) 5.273 (0.805e34.535) 7.380 (1.506e36.171)*
*p< 0.05.
NZ All pneumonia cases were fatal.
ACBLZ AmpC type b-lactamase; DTLZ dual-type lactamases; ESBLZ extended-spectrum b-lactamase.
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noglycoside susceptibility, on the other hand, were similar
among three types of isolates. Our results are in line with the
observation by Lee and colleagues,22 in which higher MIC50
and MIC90 of carbapenems, ciprofloxacin, and piperacillin-
tazobactam were demonstrated in DTL-producing K pneu-
moniae than in ESBL-producing K pneumoniae. Importantly,
the authors found patients exposed to either aminoglyco-
sides or piperacillin-tazobactam were at lower risk for ESBL-
producing K pneumoniae bacteremia, whereas exposure to
aminoglycoside but not piperacillin-tazobactam was associ-
ated with a lower risk for DTL-producing K pneumoniae
bacteremia. Thus, the risk of acquiring DTL-producing
bacteremia may be determined by differences in the
profiles of antibiotic coresistance among 3-GC resistant
bacteria. For example, piperacillin-tazobactam, to which
most ESBL- and ACBL-producing isolates remained suscep-
tible, lost activity toward many DTL-producing isolates in our
study. Therefore, use of piperacillin-tazobactam may pose
selective pressure against ESBL- and ACBL-producing
isolates, allowing DTL-producing bacteria to become the
dominant colonizers among residential microbiota. Further,
large-scale analyses of antibiotic use in temporal relation to
the evolving epidemiology of DTL-producing bacteria among
3-GCeresistant Enterobacteriaceae would provide deep
insight to this emerging issue.
In summary, our study revealed DTL-producing isolates
were increasingly prevalent among CAZ- or CTX- non-
susceptible E coli and K pneumoniae, and, not uncom-
monly, had a false-negative ESBL phenotype, according to
current CLSI guidelines for ESBL confirmation. The new CLSI
susceptibility breakpoints (CLSI-2010) for third-generation
cephalosporins were shown to be more sensitive than
previous criteria (CLSI-2009) in detecting ESBL-, ACBL-, or
DTL-producing E coli or K pneumoniae. However, since our
study was conducted retrospectively without a standard-
ized dosing schedule and sufficient patient numbers,
further generalization of our clinical data to patientsacquiring DTL-producing bacteremia is not possible. In
addition, the use of genotypes as the surrogate for actual
b-lactamase activity might underestimate case-mortality,
as a reduction in the gene expression or enzyme activity
would lead to an erroneous inflation of case numbers and
an increase in the survival rate. Nevertheless, our data are
in agreement with CLSI-2010 regulations by which routine
ESBL testing is not necessary before reporting results of
susceptibility to cephalosporins in E coli and K pneumoniae
because the revised criteria are more inclusive for the
detection of antimicrobial resistance mediated by plasmid-
borne AmpC b-lactamase and/or ESBL. This has been shown
in our study as well as others.23,24Acknowledgment
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